Cellistic

Pulse™ gives you a faster, more streamlined path through iPSC cell line development. By enabling up to 4 edits in one round with STAR-CRISPR™ multiplex editing, keeping all IP and licensing under one roof, and running your program through standardized GMP-ready workflows, Pulse helps you cut more than 12 months from the timeline while keeping every step predictable and controlled. Learn what Pulse™ can do for your program.

A standardized roadmap for NK cell therapy manufacturing. Echo™-NK delivers fixed cost (€3M), 18-month timelines, and > 20 B cells — fully GMP-compliant and powered by STAR-CRISPR™ precision.

A standardized roadmap for NK cell therapy manufacturing. Echo™-NK delivers fixed cost (€3 Million), 18-month timelines, and 20+ Billion cells — fully GMP-compliant and powered by STAR-CRISPR™ precision.

Achieving precision, efficiency, and GMP compliance in iPSC genome editing remains one of the field’s toughest challenges. This webinar will discuss current approaches to improving genome editing performance in iPSC line development, including recent evaluations of advanced systems such as STAR-CRISPR™. Topics will cover nuclease design principles, comparison of architectures, and observed outcomes related to off-target activity, multiplexing capability, and genomic stability. 👉 Register now to secure your spot and advance your iPSC editing strategy.

15+ years of iPSC-derived expertise. 32,000 sqf of manufacturing space. 100L bioreactor capacity. These aren't add-ons to a broader CDMO offering, they're the foundation Cellistic was built on. From cell line development to final drug product, Cellistic supports iPSC-derived programs with the infrastructure to match.

Most CDMOs added iPSC work onto an existing pipeline. Cellistic didn't. Every platform, from cell line development through GMP manufacturing, was built around iPSC-derived cell therapy from the start. That focus runs through Pulse™ for cell line development, Echo™ for GMP manufacturing across NK, cardiac and T cell types, and STAR-CRISPR™ for gene editing, all built on one industrialized platform rather than stitched together from generalist capabilities. Start at any stage, from a single service to the full program.